Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Codexis is a protein engineering company that develops and sells proprietary enzymes for pharmaceutical manufacturing, molecular diagnostics, and novel biotherapeutic applications. The company uses its CodeEvolver platform to design custom enzymes that enable more efficient, sustainable chemical synthesis processes, primarily serving pharmaceutical customers requiring complex chiral intermediates. With a $100M market cap, negative cash flow of $10M, and 73% revenue decline over the past year, the company faces significant execution challenges and potential capital constraints.
Codexis generates revenue through three channels: (1) selling engineered enzymes as products to pharmaceutical manufacturers who use them in API synthesis, particularly for chiral intermediates where traditional chemistry is inefficient; (2) multi-year R&D collaborations where partners pay for custom enzyme development using the CodeEvolver platform; and (3) licensing its platform technology with upfront fees, milestones, and royalties. The 73% gross margin reflects the high-value nature of specialized enzymes, but the -99% operating margin indicates the company is burning cash to fund R&D and maintain its technology platform. Pricing power depends on demonstrating cost savings versus traditional chemical synthesis (typically 20-40% reduction in manufacturing costs) and the lack of alternative biocatalytic solutions for specific reactions.
Announcements of new pharmaceutical collaboration agreements or contract wins, particularly with top-20 pharma companies
Progress updates on key customer programs transitioning from development to commercial manufacturing scale
Quarterly product revenue trends indicating adoption of existing enzyme products in commercial pharmaceutical production
Cash runway updates and financing announcements given negative $10M operating cash flow and potential need for capital raise
Regulatory approvals for drugs manufactured using Codexis enzymes, validating the technology platform
Technological obsolescence risk if competing enzyme engineering platforms (machine learning-based protein design from companies like Arzeda, Evonetix) or alternative synthesis methods (continuous flow chemistry, AI-designed small molecule routes) prove superior or more cost-effective
Pharmaceutical industry consolidation reducing the number of potential customers and increasing buyer negotiating power, particularly as top 10 pharma companies represent estimated 60-70% of addressable market
Regulatory changes requiring more extensive validation data for biocatalytic manufacturing processes, increasing customer adoption barriers and lengthening sales cycles
Large enzyme suppliers (Novozymes, DSM) expanding into pharmaceutical applications with greater scale and established customer relationships
Pharmaceutical companies developing in-house enzyme engineering capabilities rather than outsourcing to Codexis, particularly as AI/ML tools become more accessible
Academic institutions and startups offering lower-cost enzyme engineering services, commoditizing the technology and pressuring margins
Cash burn of approximately $10M annually with $100M market cap suggests potential need for dilutive equity financing within 12-18 months if revenue does not stabilize
1.78 debt/equity ratio is elevated for an unprofitable biotech, though absolute debt levels appear manageable given 4.12 current ratio
Concentration risk if top 1-2 customers represent >30% of revenue, creating vulnerability to single contract losses
Potential impairment of intangible assets or goodwill if revenue decline continues and management reassesses technology platform value
low - Pharmaceutical manufacturing is relatively recession-resistant as drug production continues regardless of economic conditions. However, biotech customer funding for R&D collaborations is moderately cyclical, as venture capital and IPO markets for biotech partners dry up during downturns. The company's revenue decline appears driven by company-specific execution issues rather than macro factors, though tighter biotech financing conditions in 2024-2025 likely contributed to collaboration revenue weakness.
Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples for unprofitable biotech companies, particularly those trading at 2.0x sales with negative cash flow; (2) tighter financial conditions reduce venture funding for biotech customers who might otherwise sign R&D collaboration agreements. However, the company's own financing costs are minimal given low debt levels (1.78 debt/equity but small absolute debt given $100M market cap). The 4.12 current ratio suggests adequate near-term liquidity, but sustained high rates could pressure the company's ability to raise growth capital on favorable terms.
Minimal direct credit exposure as the company is not a lender and has limited debt. However, customer credit quality matters indirectly - if pharmaceutical or biotech partners face financial distress, they may delay payments, cancel collaborations, or reduce enzyme purchases. The company's receivables quality depends on the financial health of its customer base, which is generally strong for large pharma but weaker for smaller biotech partners.
growth - The company attracts speculative biotech investors betting on platform technology adoption and eventual profitability inflection, despite current negative cash flow and revenue decline. The 73% one-year decline and -61% six-month return indicate momentum investors have abandoned the stock. Value investors are deterred by negative earnings, cash burn, and lack of clear path to profitability. This is a high-risk, high-potential-reward profile suitable only for investors with biotech sector expertise and tolerance for binary outcomes (successful platform adoption versus potential bankruptcy/acquisition).
high - Small-cap biotech with $100M market cap, negative cash flow, and binary contract announcement risk creates extreme volatility. The 73% one-year decline demonstrates downside volatility, while individual contract wins could drive 20-50% single-day moves. Estimated beta above 1.5 relative to broader biotech indices. Low institutional ownership and limited analyst coverage amplify price swings on low volume.
